BMJ Global Health2019;4:e001504. doi:10.1136/bmjgh-2019-00150
Int J Bipolar Disord (2018) 6:6 https://doi.org/10.1186/s40345‑017‑0110‑8
In 2001, the WHO stated that: "The use of mobile and wireless technologies to support the achievement of health objectives (mHealth) has the potential to transform the face of health service delivery across the globe".... Within mental health, interventions and monitoring systems for depression, anxiety, substance abuse, eating disorder, schizophrenia and bipolar disorder have been developed and used. The present paper presents the status and findings from studies using automatically generated objective smartphone data in the monitoring of bipolar disorder, and addresses considerations on the current literature and methodological as well as clinical aspects to consider in the future studies.
more
Front. Hum. Neurosci., 25 September 2009 | https://doi.org/10.3389/neuro.09.026.2009
Lancet Global Health Volume 6, ISSUE 2, Pe146-e147, February 01, 2018
Open AccessPublished:March 28, 2019DOI:https://doi.org/10.1016/S1473-3099(18)30730-8
The Lancet Infectious Diseases
PLoS Medicine Vol. 6 no. 10 (2009) e1000165
Lancet Global Health Volume 7, Issue 1, January 2019, Pages e81-e95
Phiri et al. Human Resources for Health (2017) 15:40
DOI 10.1186/s12960-017-0214-3
Desta et al. Int J Ment Health Syst (2018) 12:38 https://doi.org/10.1186/s13033-018-0217-z
Epilepsia, 55(4):475–482, 2014
doi: 10.1111/epi.12550
Health Services Insights Volume 10: 1–7
Lancet 2012; 380: 1193–1201
Series: Epilepsy 2
A Systematic Review and Meta-analysis
Clinical Infectious Diseases® 2016;62(12):1586–94
Original research article
Contraception 97 (2018) 439–444
https://doi.org/10.1016/j.contraception.2018.01.003
0010-7824/© 2018 The Authors. Published by Elsevier Inc.
Lancet Glob Health 2019 Published Online January 24, 2019 http://dx.doi.org/10.1016/S2214-109X(18)30479-0
The health-care system collapse underway in Venezuela is a cause of utmost concern for its people and, increasingly, for the wider region. Declines in provision of basic services, such as ...childhood immunisation, malaria control, water, sanitation, and nutritional support, have led to increasing morbidity and mortality rates from an array of preventable diseases, including malaria, measles, and diphtheria. Secondary and tertiary care have also been greatly affected, due to declining investment, out-migration of providers, and spiralling hyperinflation that has driven the country and its people into poverty.1 As is so often, and so tragically, the case, the most affected populations have been the most vulnerable: infants and children, their mothers, the poor (now the great majority of the populations), and indigenous people
more
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge...s of the clinical trials of fexinidazole. The screening of the Drugs for Neglected Diseases initiative (DNDi) HAT-library by the Swiss TPH had singled out fexinidazole, originally developed by Hoechst (now Sanofi), as the most promising of a series of over 800 nitroimidazoles and related molecules. In cell culture, fexinidazole has an IC50 of around 1 µM against Trypanosoma brucei and is more than 100-fold less toxic to mammalian cells. In the mouse model, fexinidazole cures both the first, haemolymphatic, and the second, meningoencephalitic stage of the infection, the latter at 100 mg/kg twice daily for 5 days. In patients, the clinical trials managed by DNDi and supported by Swiss TPH mainly conducted in the Democratic Republic of the Congo demonstrated that oral fexinidazole is safe and effective for use against first- and early second-stage sleeping sickness. Based on the positive opinion issued by the European Medicines Agency in 2018, the WHO has released new interim guidelines for the treatment of HAT including fexinidazole as the new therapy for first-stage and non-severe second-stage sleeping sickness caused by Trypanosoma brucei gambiense (gHAT). This greatly facilitates the diagnosis and treatment algorithm for gHAT, increasing the attainable coverage and paving the way towards the envisaged goal of zero transmission by 2030.
more